/
MEDP
$529.59-$5.13 (-0.96%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$15.1B
29M shares
52-week range
$306.70 – $628.92
69% from low
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$351.22
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $704.6M | $861.0M | $925.9M | $1.14B | $1.46B | $1.89B | $2.11B | $2.53B |
| Cost of revenue | $489.1M | $615.3M | $647.2M | $814.2M | $1.03B | $1.36B | $1.45B | $1.77B |
| Gross profit | $215.5M | $245.7M | $278.7M | $328.2M | $432.4M | $524.5M | $656.3M | $760.6M |
| Gross margin | 30.6% | 28.5% | 30.1% | 28.7% | 29.6% | 27.8% | 31.1% | 30.1% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $101.0M | $127.3M | $167.0M | $198.6M | $278.7M | $336.8M | $446.9M | $534.9M |
| EBITDA | $139.8M | $150.5M | $186.6M | $223.1M | $308.1M | $362.5M | $505.2M | $570.5M |
| Net income | $73.2M | $100.4M | $145.4M | $181.8M | $245.4M | $282.8M | $404.4M | $451.1M |
| Net margin | 10.4% | 11.7% | 15.7% | 15.9% | 16.8% | 15.0% | 19.2% | 17.8% |
| EPS (diluted) | 1.97 | 2.67 | 3.84 | 4.81 | 7.28 | 8.88 | 12.63 | 15.28 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.8B | $16.99 | $16.75–$17.31 | 9 |
| 2027 | $3.0B | $18.55 | $17.41–$19.27 | 9 |
| 2028 | $3.2B | $20.82 | $19.13–$24.50 | 9 |
| 2029 | $3.6B | $23.36 | $22.13–$25.10 | 3 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$435.83
Price
$529.59
Implied downside
-18%
Peer comparison
Medpace Holdings, Inc. Common Stock
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
www.medpace.com- Employees
- 6,300
- IPO / List date
- Aug 11, 2016
- HQ
- CINCINNATI, OH
Held by traders on TradeandTell
No one on the platform currently holds MEDP.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 504,668 | $242.3M |
| Bridgewater Associatesas of 2026-03-31 | 41,135 | $19.8M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded MEDP yet.
